Current advances in immunotherapy for pancreatic cancer

Current Problems in Cancer

Volumn 37, Issue 5, 2013, Pages 273-279

  Uram, Jennifer N ^a   Le, Dung T ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALGENPANTUCEL L; ANZ 100; BMS 936559; CA 19-9 ANTIGEN; CANCER VACCINE; CAPECITABINE; CRS 207; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IPILIMUMAB; IRINOTECAN; MESOTHELIN; MONOCLONAL ANTIBODY; OXALIPLATIN; PD L1 ANTIBODY; TERTOMOTIDE; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CELL IMMORTALIZATION; DENDRITIC CELL; DISEASE FREE SURVIVAL; DRUG SAFETY; FOLLOW UP; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; INNATE IMMUNITY; LISTERIA MONOCYTOGENES; LOW DRUG DOSE; MOLECULAR RECOGNITION; NATURAL KILLER CELL; NONHUMAN; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); T LYMPHOCYTE ACTIVATION;

CARCINOMA, PANCREATIC DUCTAL; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; PANCREATIC NEOPLASMS;

EID: 84890180205     PISSN: 01470272     EISSN: 15356345     Source Type: Journal    
DOI: 10.1016/j.currproblcancer.2013.10.004     Document Type: Article

References (37)

1. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363(8):711-723. [Epub 2010/06/08].
2. Brahmer J.R., Drake C.G., Wollner I., et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010, 28(19):3167-3175. [Epub 2010/06/03].
3. Brahmer J.R., Tykodi S.S., Chow L.Q., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366(26):2455-2465. [Epub 2012/06/05].
4. Topalian S.L., Hodi F.S., Brahmer J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366(26):2443-2454. [Epub 2012/06/05].
5. Tabernero J, Powderly JD, Hamid O, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic CRC, gastric cancer (GC), SCCHN, or other tumors. ASCO Meeting Abstracts 2013;31(15_suppl):3622.
6. Kantoff P.W., Higano C.S., Shore N.D., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363(5):411-422. [Epub 2010/09/08].
7. Bernhardt S.L., Gjertsen M.K., Trachsel S., et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study. Br J Cancer 2006, 95(11):1474-1482. [Epub 2006/10/25].
8. Buanes T, Maurel J, Liauw W, et al. Randomized phase III study of gemcitabine (G) versus GV1001 in sequential combination with G in patients with unresectable and metastatic pancreatic cancer (PC). ASCO Meeting Abstracts 2009;27(15S):4601.
9. Middleton GW, Valle JW, Wadsley J, et al. A phase III randomized trial of chemoimmunotherapy comprising gemcitabine and capecitabine with or without telomerase vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer. ASCO Meeting Abstracts 2013;31(18_suppl):LBA4004.
10. Herrmann R., Bodoky G., Ruhstaller T., et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007, 25(16):2212-2217. [Epub 2007/06/01].
11. Press release. Available from:. http://www.businesswire.com/news/home/20130603005934/en/Final-Results-Phase-III-TeloVac-Trial-Pancreatic.
12. Hardacre J.M., Mulcahy M., Small W., et al. Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study. J Gastrointest Surg 2013, 17(1):94-100. [discussion p-1. Epub 2012/12/12].
13. Galili U. Anti-Gal: an abundant human natural antibody of multiple pathogeneses and clinical benefits. Immunology 2013, [Epub 2013/04/13].
14. Hardacre JM, Mulcahy MF, Small W, et al. Addition of algenpantucel-L immunotherapy to standard of care (SOC) adjuvant therapy for pancreatic cancer. ASCO Meeting Abstracts 2012;30(15_suppl):4049.
15. Rossi GR, Hardacre JM, Mulcahy MF, et al. Effect of algenpantucel-L immunotherapy for pancreatic cancer on anti-mesothelin antibody (Ab) titers and correlation with improved overall survival. ASCO Meeting Abstracts 2013;31(15_suppl):3007.
16. Jaffee E.M., Hruban R.H., Biedrzycki B., et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001, 19(1):145-156. [Epub 2001/01/03].
17. Laheru D., Lutz E., Burke J., et al. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res 2008, 14(5):1455-1463. [Epub 2008/03/05].
18. Lutz E., Yeo C.J., Lillemoe K.D., et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A phase II trial of safety, efficacy, and immune activation. Ann Surg 2011, 253(2):328-335. [Epub 2011/01/11].
19. Argani P., Iacobuzio-Donahue C., Ryu B., et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 2001, 7(12):3862-3868. [Epub 2001/12/26].
20. Thomas A.M., Santarsiero L.M., Lutz E.R., et al. Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med 2004, 200(3):297-306. [Epub 2004/08/04].
21. Zheng L, Edil B, Nguyen T, et al. Novel tertiary lymphoid aggregates induced in pancreatic adenocarcinoma by an allogeneic GM-CSF secreting pancreatic tumor vaccine as a neoadjuvant treatment. ASCO Gastrointestinal Cancers Abstracts 157. 2010.
22. Le D.T., Brockstedt D.G., Nir-Paz R., et al. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res 2012, 18(3):858-868. [Epub 2011/12/08].
23. Ino Y., Yamazaki-Itoh R., Shimada K., et al. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer 2013, 108(4):914-923. [Epub 2013/02/07].
24. Liyanage U.K., Moore T.T., Joo H.G., et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002, 169(5):2756-2761. [Epub 2002/08/24].
25. Hiraoka N., Onozato K., Kosuge T., et al. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res 2006, 12(18):5423-5434. [Epub 2006/09/27].
26. Chen L., Flies D.B. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 2013, 13(4):227-242. [Epub 2013/03/09].
27. Grosso J.F., Jure-Kunkel M.N. CTLA-4 blockade in tumor models: an overview of preclinical and translational research. Cancer Immunol 2013, 13:5. [Epub 2013/02/08].
28. Selby M.J., Engelhardt J.J., Quigley M., et al. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 2013, [Epub 2013/04/07].
29. Royal R.E., Levy C., Turner K., et al. Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 2010, 33(8):828-833. [Epub 2010/09/16].
30. Freeman G.J., Long A.J., Iwai Y., et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000, 192(7):1027. [Epub 2000/10/04].
31. Latchman Y., Wood C.R., Chernova T., et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001, 2(3):261-268. [Epub 2001/02/27].
32. Bigelow E., Bever K.M., Xu H., et al. Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue. J Vis Exp 2013, (71). [Epub 2013/01/19].
33. Kuang D.M., Zhao Q., Peng C., et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med 2009, 206(6):1327-1337. [Epub 2009/05/20].
34. Currie A.J., Prosser A., McDonnell A., et al. Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation. J Immunol 2009, 183(12):7898-7908. [Epub 2009/12/17].
35. Iwai Y., Ishida M., Tanaka Y., et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002, 99(19):12293-12297. [Epub 2002/09/10].
36. Lipson E.J., Sharfman W.H., Drake C.G., et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res 2013, 19(2):462-468. [Epub 2012/11/22].
37. Le DT, Lutz E, Uram JN, et al. Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother 2013;36(7):382-9. doi:. http://10.1097/CJI.0b013e31829fb7a2.